Open-label, randomized crossover/wait-list study (n=30) testing two psilocybin sessions (20 mg, then 30 mg if tolerated) for treatment of OCD.
This open-label, randomized crossover with wait-list control investigates feasibility, safety, and preliminary efficacy of two psilocybin sessions for adults with OCD; sessions occur approximately two weeks apart.
Primary outcomes include safety, acceptability, and change in OCD symptoms (Y-BOCS); secondary measures examine cognition, model-based learning, ERN, affect, social connection, movement, and quality of life with follow-up to six months.
Assessments occur at screening, during each psilocybin session, and at multiple follow-up visits; two dosing sessions use 20 mg as initial dose and 30 mg as a second session if well tolerated.
Receive two psilocybin sessions (20 mg first, then 30 mg if well tolerated) approximately two weeks apart.
Second session 30 mg if well tolerated; sessions ~2 weeks apart.
Wait-list control receiving identical psilocybin dosing after wait period (20 mg then 30 mg if tolerated).
Wait-list crossover to same dosing schedule; 20 mg then 30 mg if tolerated.